2024-11-08 - Analysis Report
## Teladoc Health Inc (TDOC) Stock Analysis Report 

**Company Overview:** Teladoc Health Inc is a leading provider of telehealth services, offering virtual healthcare consultations and treatment through its digital platform.

**Performance Analysis:**

**1) Relative Performance:**
* **Current Cumulative Return:** 53.56%
* **S&P 500 (VOO) Cumulative Return:** 138.41%
* **Lag:** -84.85% (Relative Lag: 0.1, meaning it currently sits at the 10th percentile of historical relative performance against the S&P 500).

**Alpha and Beta Analysis:**
| Year | CAGR | MDD | Alpha | Beta |
|------|------|----------|-----|-------|
| 2015-2017 | 83.4% | 54.5% | 53.2% | 1.3 |
| 2016-2018 | 175.5% | 46.7% | 150.9% | 1.7 |
| 2017-2019 | 407.4% | 46.7% | 364.3% | 1.8 |
| 2018-2020 | 452.4% | 46.7% | 413.3% | 0.6 |
| 2019-2021 | 90.6% | 55.8% | 0.8% | 0.5 |
| 2020-2022 | -71.6% | 61.0% | -89.3% | 0.8 |
| 2021-2023 | -89.3% | 64.9% | -118.1% | 2.0 |
| 2022-2024 | -90.1% | 45.9% | -113.8% | 2.0 |
**Analysis:** TDOC has shown significant volatility in its performance, especially in recent years. While it exhibited strong growth in earlier periods (2015-2020), it has been significantly underperforming the S&P 500 since 2021. Its beta, which measures volatility relative to the market, has been fluctuating, suggesting a high sensitivity to market movements. 

**2) Recent Price Movements:**
* **Last Price:** 9.44 
* **5-Day Moving Average:** 9.13
* **20-Day Moving Average:** 9.16
* **60-Day Moving Average:** 8.36
**Analysis:** The stock is currently trading slightly above its short-term moving averages (5-day and 20-day), suggesting potential for continued upward movement. However, it's lagging significantly behind its 60-day moving average, indicating a longer-term downtrend. 

**3) Technical Indicators:**
* **RSI:** 49.08 (Neutral)
* **PPO:** -0.13 (Slight bearish)
* **Delta_Previous_Relative_Divergence:** -0.67 (Negative, suggesting recent short-term downtrend)
* **Expected Return:** 0.0% (over S&P 500, long-term)

**4) Recent Earnings and Outlook:**
| Date | EPS | Revenue |
|---|---|---|
| 2024-10-31 | -0.19 | 0.64 B$ |
| 2024-08-01 | -4.92 | 0.64 B$ |
| 2024-04-26 | -0.49 | 0.65 B$ |
| 2023-10-27 | -0.35 | 0.66 B$ |
| 2024-10-31 | -0.35 | 0.66 B$ |

**Analysis:** TDOC has been consistently reporting negative earnings, indicating a challenging financial situation. The recent earnings call (2024-10-31) showed a slight improvement in EPS compared to the previous quarter, but the revenue growth remains stagnant.  While analysts are currently awaiting the next earnings report, the long-term outlook appears uncertain. 

**5) Financial Information:**

**Revenue and Profitability:**
| Quarter | Revenue | Profit Margin |
|---|---|---|
| 2024-09-30 | $0.64B | 71.94% |
| 2024-06-30 | $0.64B | 70.73% |
| 2024-03-31 | $0.65B | 69.89% |
| 2023-12-31 | $0.66B | 70.72% |
| 2023-09-30 | $0.66B | 71.83% |

**Capital and Profitability:**
| Quarter | Equity | ROE |
|---|---|---|
| 2024-09-30 | $1.51B | -2.21% |
| 2024-06-30 | $1.50B | -55.77% |
| 2024-03-31 | $2.29B | -3.58% |
| 2023-12-31 | $2.33B | -1.24% |
| 2023-09-30 | $2.29B | -2.49% |

**Analysis:** While TDOC maintains a healthy profit margin, its revenue growth appears stagnant. The negative ROE indicates a lack of profitability from its current equity base, raising concerns about its long-term sustainability.

**6) News and Recent Issues:**

* **Recent Earnings:** The most recent earnings release on October 31, 2024, was met with a mixed reaction. While analysts were expecting slightly better EPS, the report still highlighted ongoing challenges within the business. 
* **Market Outlook:** According to analysts, TDOC faces significant headwinds in the coming years, including increased competition in the telehealth market, concerns about future regulatory changes, and the need for continued investment in technology to remain competitive. 
* **Analyst Opinions:** Many analysts have downgraded their rating and price targets for TDOC, citing concerns about profitability and long-term growth prospects. 

**7) Overall Analysis:**

Teladoc Health is currently facing a challenging market environment. While the company boasts a strong brand name and significant market share in telehealth, its recent performance has been marked by declining earnings, stagnant revenue growth, and a volatile stock price. 

* **Strengths:** Strong brand recognition, established market position in telehealth, potential for future growth in a rapidly evolving industry.
* **Weaknesses:** Negative earnings, stagnant revenue growth, high debt levels, intense competition, regulatory uncertainty.

**Overall:** Given the current situation, TDOC presents a high-risk investment. While its future prospects in the telehealth sector remain promising, the company needs to address its profitability issues and demonstrate sustainable growth in order to regain investor confidence. 

**Important Note:** This analysis is based on publicly available information and does not constitute financial advice. Please consult with a qualified financial advisor before making any investment decisions.
